Alizapride HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317167

CAS#: 59338-87-3 (Alizapride HCl) ; 59338-93-1 (Alizapride)

Description: Alizapride HCl (Litican, Plitican, Superan, Vergentan) is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide and other benzamides.


Chemical Structure

img
Alizapride HCl
CAS# 59338-87-3 (Alizapride HCl) ; 59338-93-1 (Alizapride)

Theoretical Analysis

MedKoo Cat#: 317167
Name: Alizapride HCl
CAS#: 59338-87-3 (Alizapride HCl) ; 59338-93-1 (Alizapride)
Chemical Formula: C16H22ClN5O2
Exact Mass:
Molecular Weight: 351.84
Elemental Analysis: C, 54.62; H, 6.30; Cl, 10.08; N, 19.91; O, 9.09

Price and Availability

Size Price Availability Quantity
50.0mg USD 190.0 2 Weeks
100.0mg USD 280.0 2 Weeks
Bulk inquiry

Related CAS #: 59338-87-3 (Alizapride HCl) ; 59338-93-1 (Alizapride)  

Synonym: Alizapride; 59338-93-1; Limican; Plitican; Vergentan; Superan; Alizaprida; Litican; MS 5080; MS5080; MS-5080

IUPAC/Chemical Name: 6-Methoxy-N-[[1-(2-propenyl)-2-pyrrolidinyl]methyl]-1H-benzotriazole-5-carboxamide Hydrochloride

InChi Key: BRECEDGYMYXGNF-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H21N5O2.ClH/c1-3-6-21-7-4-5-11(21)10-17-16(22)12-8-13-14(19-20-18-13)9-15(12)23-2;/h3,8-9,11H,1,4-7,10H2,2H3,(H,17,22)(H,18,19,20);1H

SMILES Code: O=C(C1=C(OC)C=C(NN=N2)C2=C1)NCC3N(CC=C)CCC3.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 351.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Huvelle S, Godet M, Gillet P, Jamart J, Galanti L, Hecq JD. [Physical compatibility of a mixture of alizapride and dexamethasone in flexible infusion bags of 100 ml of 0.9% NaCl]. J Pharm Belg. 2015 Jun;(2):38-9. French. PubMed PMID: 26466508.

2: Dewinter G, Teunkens A, Vermeulen K, Devroe S, Van Hemelrijck J, Meuleman C, Vergote I, Fieuws S, Van de Velde M, Rex S. Alizapride and ondansetron for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic gynaecological surgery: A double-blind, randomised, placebo-controlled noninferiority study. Eur J Anaesthesiol. 2015 Jun 16. [Epub ahead of print] PubMed PMID: 26086285.

3: Anrys P, Magnette A, Jamart J, Galanti L, Hecq JD. [Physical compatibility of a mixture of alizapride and clorazepate in flexible infusion bags of 100 ml of 5% glucose]. J Pharm Belg. 2014 Sep;(3):38-9. French. PubMed PMID: 25226762.

4: Aprile S, Del Grosso E, Grosa G. In vitro metabolic fate of alizapride: evidence for the formation of reactive metabolites based on liquid chromatography-tandem mass spectrometry. J Mass Spectrom. 2012 Jun;47(6):737-50. doi: 10.1002/jms.3011. PubMed PMID: 22707166.

5: Athanasopoulos A, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L. Long-term stability of the hydrochlorides of tramadol and alizapride in dextrose 5% polyolefin bag at 5+/-3 degrees C. Ann Pharm Fr. 2010 May;68(3):157-62. doi: 10.1016/j.pharma.2010.03.004. Epub 2010 May 15. PubMed PMID: 20569772.

6: Tamaro I, Aprile S, Giovenzana GB, Grosa G. Development and validation of a stability-indicating HPLC-UV method for the determination of alizapride and its degradation products. J Pharm Biomed Anal. 2010 Apr 6;51(5):1024-31. doi: 10.1016/j.jpba.2009.10.026. Epub 2009 Nov 6. PubMed PMID: 19962264.

7: Horta ML, Morejon LC, da Cruz AW, Dos Santos GR, Welling LC, Terhorst L, Costa RC, Alam RU. Study of the prophylactic effect of droperidol, alizapride, propofol and promethazine on spinal morphine-induced pruritus. Br J Anaesth. 2006 Jun;96(6):796-800. Epub 2006 Apr 5. PubMed PMID: 16597655.

8: Horta ML, Vianna PT. Effect of intravenous alizapride on spinal morphine-induced pruritus. Br J Anaesth. 2003 Aug;91(2):287-9. PubMed PMID: 12878632.

9: Rey E, Stettler E, D'athis P, Pons G. Pharmacokinetics of alizapride in children receiving chemotherapy for solid tumour. Fundam Clin Pharmacol. 2001 Jun;15(3):217-20. PubMed PMID: 11468033.

10: Münstedt K, Wunderlich I, Blauth-Eckmeyer E, Zygmunt M, Vahrson H. Does dexamethasone enhance the efficacy of alizapride in cis-platinum-induced delayed vomiting and nausea? Oncology. 1998 Jul-Aug;55(4):293-9. PubMed PMID: 9663418.